Stocks and Investing Stocks and Investing
Fri, April 26, 2024
Thu, April 25, 2024

Mohit Bansal Maintained (BMRN) at Buy with Increased Target to $110 on, Apr 25th, 2024


Published on 2024-10-28 10:40:02 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $100 to $110 on, Apr 25th, 2024.

Mohit has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Reiterated at Hold and Held Target at $91 on, Thursday, February 29th, 2024
  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Friday, February 23rd, 2024


These are the ratings of the 2 analyists that currently disagree with Mohit


  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $107 on, Friday, February 23rd, 2024
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $104 on, Tuesday, January 30th, 2024